Home    Back

Target Gene/Pathway💬 Info on mouse-over

e.g. Sirolimus, Adalimumab, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

57 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank Disease ID
1 African trypanosomiasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
2 African trypanosomiasis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
4 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
5 Alzheimer disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
6 Alzheimer disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
7 Alzheimer disease 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
8 Amoebiasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
9 Amoebiasis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
10 Amoebiasis 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
11 Amyotrophic lateral sclerosis 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
12 Antifolate resistance 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
13 Antifolate resistance 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
14 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
15 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
16 Cellular senescence 💬
 [1] IL1A 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
17 Chagas disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
18 Chagas disease 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
19 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
20 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
21 Coronavirus disease - COVID-19 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
22 Cytokine-cytokine receptor interaction 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
23 Cytokine-cytokine receptor interaction 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
24 Cytokine-cytokine receptor interaction 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
25 Cytokine-cytokine receptor interaction 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
26 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
27 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
28 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
29 Fluid shear stress and atherosclerosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
30 Fluid shear stress and atherosclerosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
31 Fluid shear stress and atherosclerosis 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
32 Gap junction 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
33 Graft-versus-host disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
34 Graft-versus-host disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
35 Hematopoietic cell lineage 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
36 Hematopoietic cell lineage 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
37 Hematopoietic cell lineage 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
38 Hematopoietic cell lineage 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
39 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
40 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
41 HIF-1 signaling pathway 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
42 Human cytomegalovirus infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
43 Human cytomegalovirus infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
44 Human cytomegalovirus infection 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
45 Human cytomegalovirus infection 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
46 Human T-cell leukemia virus 1 infection 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
47 Huntington disease 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
48 IL-17 signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
49 IL-17 signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
50 Inflammatory bowel disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
51 Inflammatory bowel disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
52 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
53 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
54 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
55 Influenza A 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
56 Influenza A 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
57 JAK-STAT signaling pathway 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
58 Legionellosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
59 Legionellosis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
60 Leishmaniasis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
61 Leishmaniasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
62 Malaria 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
63 Malaria 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
64 MAPK signaling pathway 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
65 MAPK signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
66 MAPK signaling pathway 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
67 Measles 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
68 Measles 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
69 Necroptosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
70 Necroptosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
71 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
72 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
73 NF-kappa B signaling pathway 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
74 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
75 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
76 Non-alcoholic fatty liver disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
77 Non-alcoholic fatty liver disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
78 Non-alcoholic fatty liver disease 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
79 Osteoclast differentiation 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
80 Osteoclast differentiation 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
81 Osteoclast differentiation 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
82 Parkinson disease 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
83 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
84 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
85 Pathogenic Escherichia coli infection 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
86 Pathogenic Escherichia coli infection 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
87 Pathways in cancer 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
88 Pathways of neurodegeneration - multiple diseases 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
89 Pathways of neurodegeneration - multiple diseases 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
90 Pathways of neurodegeneration - multiple diseases 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
91 Pertussis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
92 Pertussis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
93 Phagosome 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
94 PI3K-Akt signaling pathway 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
95 Prion disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
96 Prion disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
97 Prion disease 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
98 Prostate cancer 💬
 [1] IL1R2 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
99 Rheumatoid arthritis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
100 Rheumatoid arthritis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
101 Salmonella infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
102 Salmonella infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
103 Salmonella infection 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
104 Shigellosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
105 Shigellosis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
106 Shigellosis 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
107 Th17 cell differentiation 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
108 Th17 cell differentiation 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
109 Th17 cell differentiation 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
110 Th17 cell differentiation 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
111 TNF signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
112 TNF signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
113 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
114 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
115 Transcriptional misregulation in cancer 💬
 [1] IL1R2 💬 D02934 💬 Anakinra [19]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
116 Tuberculosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
117 Tuberculosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
118 Type I diabetes mellitus 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
119 Type I diabetes mellitus 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
120 Viral protein interaction with cytokine and cytokine receptor 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [18]  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
121 Yersinia infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
122 Yersinia infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬

Back to top